“The third quarter of 2025 marked the achievement of a significant milestone with the completion of our NDA submission for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC. We look forward to working closely with the FDA throughout the review process, as well as continuing to engage with the agency on potential opportunities for line-agnostic expansion,” said Darlene Noci, Chief Development Officer of Nuvalent (NUVL). “We remain on track to share topline pivotal data this quarter from our ALKOVE-1 trial of neladalkib in TKI pre-treated advanced ALK-positive NSCLC, and continue to progress ALKAZAR, our global Phase 3 randomized, controlled trial of neladalkib for TKI-naive patients with advanced ALK-positive NSCLC.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVL:
- Nuvalent’s Zidesamtinib Study: A Potential Game-Changer in Cancer Treatment
- Nuvalent’s Promising Phase 3 Study: A Potential Game-Changer in NSCLC Treatment
- Nuvalent’s NVL-330 Study: A Potential Game-Changer for HER2-Altered NSCLC
- Nuvalent’s ALKOVE-1 Study: A Potential Game-Changer in ALK-Positive Cancer Treatment
- 3 Best Stocks to Buy Now, 10/27/2025, According to Top Analysts